Acorda Therapeutics, Inc. (NASDAQ:ACOR) management will conduct a conference call for 4th August 2020 at 4:30 PM Eastern Time to discuss financial results and companys performance for 2Q20.
The conference call will also be available live on the website www.acorda.com
Earnings Expectation
Acorda Therapeutics, Inc. is set to announce second quarter earning results on Tuesday 4th August 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, ACOR to report 2Q20 loss of $ 0.48 per share. For the full year, analysts anticipate top line of $ 118.10 million, while looking forward to loss of $ 1.86 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 130.00 million ~ $ 160.00 million
Click Here For More Historical Outlooks Of Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.
